Related Experiment Video
Updated: Jul 11, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Management of Hypertension in Diabetic Kidney Disease
Gates B Colbert1, Mohamed E Elrggal2, Anna Gaddy3
1Division of Nephrology, Texas A&M University College of Medicine at Dallas, Dallas, TX 75246, USA.
Insights
Controlling hypertension significantly delays diabetic kidney disease progression. Current treatments focus on the renin-angiotensin-aldosterone system, SGLT2 inhibitors, and MRAs, with new agents emerging for this growing patient population.
Area of Science:
- Nephrology
- Cardiology
- Endocrinology
Background:
- Hypertension accelerates cardiovascular disease and diabetic kidney disease (DKD) progression.
- The precise relationship between hypertension and DKD progression is debated, but control is proven beneficial.
- DKD affects a growing population, necessitating advanced treatment strategies.
Purpose of the Study:
- To review current and emerging pharmacologic treatments for hypertension in DKD patients.
- To highlight medications targeting the renin-angiotensin-aldosterone system (RAAS).
- To discuss guideline-changing therapies like SGLT2 inhibitors and novel MRAs.
Main Methods:
- Review of existing literature and clinical experience with antihypertensive medications in DKD.
- Focus on drug classes proven effective in managing hypertension and slowing DKD progression.
- Discussion of emerging pharmacologic agents and their potential impact.
Main Results:
- Control of hypertension, particularly within guideline-recommended ranges, demonstrably slows DKD progression.
- RAAS inhibitors remain a cornerstone of treatment.
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors and newer mineralocorticoid receptor antagonists (MRAs) represent significant advancements.
Conclusions:
- Effective hypertension management is crucial for mitigating DKD progression.
- A combination of established and novel pharmacotherapies offers improved outcomes.
- Ongoing research into new drug classes is vital for optimizing care in this complex patient group.
Abstract:
Hypertension is a critical component of cardiovascular disease progression in patients with chronic kidney disease, and specifically diabetic kidney disease (DKD). Causation versus correlation remains up for debate, but what has been confirmed is the delay of DKD progression when hypertension is controlled or moved to guideline drive ranges. Many medications have been studied and used in real world experience for best outcomes, and we discuss below the proven winners thus far making up the renin angiotensin aldosterone system. As well, we discuss guideline changing medications including sodium-glucose cotransporter 2 inhibitors and newer generation mineralocorticoid receptor antagonists. With the growing prevalence of diabetes and DKD in the population, newer agents are emerging in multiple drug class and will be highlighted below. Clinicians continue to search for the optimal care plans for this challenging patient population.
More Related Videos
10:37Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Antihypertensive Drugs: Action of Diuretics
Chronic Kidney Disease IV: Nursing Management
Hypertension V: Nursing Management
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Hypertension IV: Drug Therapy and Lifestyle Modifications